Pharma adapts to external pressure by rewriting investment, deal and partnership models. Europe’s low-price model clashes with Big Pharma’s investment logic: access to innovative drugs, manufacturing localisation and new projects are increasingly tied to predictable price regulation.
The patent cliff lifts demand for M&A and licensing, yet quality biotechs gain alternatives to a straight sale (IPO, partnerships, self-commercialisation).
China’s contradictory role: political pressure rises, but global pharma interest in Chinese pipelines does not fall — they remain a key external innovation source.
Corporate Desk (Business Validation): • Chinese pipeline due diligence is a distinct workstream (IP, clinical data, export controls); • “innovation access vs geopolitical risk” scenarios must be explicit in go/no-go; • EU/US localisation may be a deal condition, not an option.
Source: Global Business Monitoring, issue 2/2026 (HSE Faculty of World Economy and International Affairs). Adapted for Corporate APAC Desk / Country radar.